Therapeutic Study of Cinnamic Acid Derivative for Oxidative Stress Ablation: The Computational and Experimental Answers
Tekijät: Ojo, Oluwafemi Adeleke; Ogunlakin, Akingbolabo Daniel; Maimako, Rotdelmwa Filibis; Gyebi, Gideon Ampoma; Olowosoke, Christopher Busayo; Taiwo, Odunayo Anthonia; Elebiyo, Tobiloba Christiana; Adeniyi, David; David, Bolaji; Iyobhebhe, Matthew; Adetunji, Juliana Bunmi; Ayokunle, Damilare IyinKristi; Ojo, Adebola Busola; Mothana, Ramzi A.; Alanzi, Abdullah R.
Kustantaja: MDPI
Kustannuspaikka: BASEL
Julkaisuvuosi: 2023
Journal: Molecules
Tietokannassa oleva lehden nimi: MOLECULES
Lehden akronyymi: MOLECULES
Artikkelin numero: 7425
Vuosikerta: 28
Numero: 21
Sivujen määrä: 23
eISSN: 1420-3049
DOI: https://doi.org/10.3390/molecules28217425
This study aimed to examine the therapeutic activity of the cinnamic acid derivative KAD-7 (N '-(2,4-dichlorobenzylidene)-3-(4-methoxyphenyl) acrylohydrazide) on Fe2+-induced oxidative hepatic injury via experimental and computational models. In addition, the role of ATPase and ectonucleoside triphosphate diphosphohydrolase (ENTPDase) in the coordination of cellular signals is speculated upon to proffer suitable therapeutics for metabolic stress disorder upon their inhibition. While we know little about therapeutics with flexible dual inhibitors for these protein targets, this study was designed to screen KAD-7's (N '-(2,4-dichlorobenzylidene)-3-(4-methoxyphenyl) acrylohydrazide) inhibitory potential for both protein targets. We induced oxidative hepatic damage via the incubation of hepatic tissue supernatant with 0.1 mM FeSO4 for 30 min at 37 degrees C. We achieved the treatment by incubating the hepatic tissues with KAD-7 under the same conditions. The catalase (CAT), glutathione (GSH), malondialdehyde (MDA), ATPase, and ENTPDase activity were all measured in the tissues. We predicted how the drug candidate would work against ATPase and ENTPDase targets using molecular methods. When hepatic injury was induced, there was a significant decrease in the levels of the GSH, CAT, and ENTPDase (p < 0.05) activities. In contrast, we found a noticeable rise in the MDA levels and ATPase activity. KAD-7 therapy resulted in lower levels of these activities overall (p < 0.05), as compared to the control levels. We found the compound to have a strong affinity for ATPase (-7.1 kcal/mol) and ENTPDase (-7.4 kcal/mol), and a better chemical reactivity than quercetin. It also met all drug-likeness parameters. Our study shows that KAD-7 can protect the liver from damage caused by FeSO4 by reducing oxidative stress and purinergic actions. Our studies indicate that KAD-7 could be developed as a therapeutic option since it can flexibly inhibit both ATPase and ENTPDase
